NCT04611893Completed
Monitoring of NOAC Therapy: Standardizing Reference Intervals
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
This study is aimed to establish reference intervals of NOAC (dabigatran, apixaban and rivaroxaban) in ethnic Chinese patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 308 (actual)
- First submitted
- 27 Oct 2020
- Start date
- 5 Nov 2020
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Stroke
- NCT number
- NCT04611893
What you commit to
- Study type: Observational
- Participants enrolled: 308
- From 5 Nov 2020 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Recent haemorrhage or ischemia within 1 year
- Active liver disease
- Thromboembolic tendency other than atrial fibrillation (e.g. antiphospholipid syndrome, protein C, S, anti-thrombin III deficiency)
- Anticoagulation for disorders other than AF
Other
- Valvular atrial fibrillation or no atrial fibrillation
- Abnormal baseline clotting profile
- Abnormal baseline thrombocytopenia or thrombocytosis
- Non-compliant patients, defined as missing any doses of NOAC in recent 1 month
- Pregnancy
Who the study is looking for
- Ethnic Chinese ONLY
- 18 years old or above
- Non-valvular atrial fibrillation
- Duration of NOAC use at least 3 months
- No changes in NOAC dosage or type within 3 months
- Creatinine Clearance (by Cockcroft-Gault formula) \>/=30mL/min
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.